![Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy | npj Breast Cancer Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy | npj Breast Cancer](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41523-019-0137-3/MediaObjects/41523_2019_137_Fig1_HTML.png)
Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy | npj Breast Cancer
![Findings from Can-Fite's Phase II Liver Cancer Study were Presented at ASCO Annual Meeting Late-Breaking Session | Business Wire Findings from Can-Fite's Phase II Liver Cancer Study were Presented at ASCO Annual Meeting Late-Breaking Session | Business Wire](https://mms.businesswire.com/media/20190603005396/en/724676/5/ASCO_PR_Figure_1.jpg)
Findings from Can-Fite's Phase II Liver Cancer Study were Presented at ASCO Annual Meeting Late-Breaking Session | Business Wire
PLOS ONE: Bisphosphonates in the Adjuvant Setting of Breast Cancer Therapy—Effect on Survival: A Systematic Review and Meta-Analysis
![OncologyEducation on Twitter: "Dr. Salomon Stemmer provides an update of Namodenoson in patients with Child-Pugh B hepatocellular carcinoma in this video from #ASCO19: https://t.co/82i6FiEBcN… https://t.co/3aAVqpqbMy" OncologyEducation on Twitter: "Dr. Salomon Stemmer provides an update of Namodenoson in patients with Child-Pugh B hepatocellular carcinoma in this video from #ASCO19: https://t.co/82i6FiEBcN… https://t.co/3aAVqpqbMy"](https://pbs.twimg.com/media/D_6690LWwAEYsfW.png)
OncologyEducation on Twitter: "Dr. Salomon Stemmer provides an update of Namodenoson in patients with Child-Pugh B hepatocellular carcinoma in this video from #ASCO19: https://t.co/82i6FiEBcN… https://t.co/3aAVqpqbMy"
![PDF) Posttraumatic Growth in Breast Cancer Survivors: Constructive and Illusory Aspects | Ruth Pat-Horenczyk, Shlomit Perry, Yuval Ziv, Salomon Stemmer, and Yaira Hamama-raz - Academia.edu PDF) Posttraumatic Growth in Breast Cancer Survivors: Constructive and Illusory Aspects | Ruth Pat-Horenczyk, Shlomit Perry, Yuval Ziv, Salomon Stemmer, and Yaira Hamama-raz - Academia.edu](https://0.academia-photos.com/attachment_thumbnails/38986782/mini_magick20180819-29744-1budfvz.png?1534667466)
PDF) Posttraumatic Growth in Breast Cancer Survivors: Constructive and Illusory Aspects | Ruth Pat-Horenczyk, Shlomit Perry, Yuval Ziv, Salomon Stemmer, and Yaira Hamama-raz - Academia.edu
The association between infections and chemotherapy interruptions among cancer patients: Prospective cohort study
![New Long-Term Outcomes Data Reconfirm Value of Oncotype DX Breast Recurrence Score® Test to Target Chemotherapy | WebMagspace New Long-Term Outcomes Data Reconfirm Value of Oncotype DX Breast Recurrence Score® Test to Target Chemotherapy | WebMagspace](https://www.webmagspace.com/wp-content/uploads/2019/03/data-analysis-business-plan-1024x683-840x440.jpg)
New Long-Term Outcomes Data Reconfirm Value of Oncotype DX Breast Recurrence Score® Test to Target Chemotherapy | WebMagspace
PLOS ONE: Factors Affecting Communication Patterns between Oncology Staff and Family Members of Deceased Patients: A Cross-Sectional Study
![Findings from Can-Fite's Phase II Liver Cancer Study were Presented at ASCO Annual Meeting Late-Breaking Session | Business Wire Findings from Can-Fite's Phase II Liver Cancer Study were Presented at ASCO Annual Meeting Late-Breaking Session | Business Wire](https://mms.businesswire.com/media/20190603005396/en/633723/5/Can-Fite_logo_no_shadow_%5B1%5D.jpg)
Findings from Can-Fite's Phase II Liver Cancer Study were Presented at ASCO Annual Meeting Late-Breaking Session | Business Wire
![Doxorubicin-induced ovarian toxicity – topic of research paper in Veterinary science. Download scholarly article PDF and read for free on CyberLeninka open science hub. Doxorubicin-induced ovarian toxicity – topic of research paper in Veterinary science. Download scholarly article PDF and read for free on CyberLeninka open science hub.](https://cyberleninka.org/viewer_images/305083/f/1.png)